Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major ...

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...

The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA ...

Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you ...

Moderna shares surged more than 170 percent in a single session after a personalized messenger RNA cancer vaccine ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...

The vaccine, when combined with the immunotherapy drug Keytruda, reduced skin cancer recurrence and the results were ...

Moderna and Merck's personalised cancer vaccine succeeds in a Phase 3 trial, raising hopes for a new generation of cancer ...